112 related articles for article (PubMed ID: 29288559)
21. Reconsideration of BCR-ABL protein flow cytometric immunobead assay: how potent to diagnose and monitor chronic myeloid leukemia?
Kelani R; Monem F
Int J Lab Hematol; 2015 Oct; 37(5):723-8. PubMed ID: 26059167
[TBL] [Abstract][Full Text] [Related]
22. Cytogenetics in the management of "chronic myeloid leukemia": an update by the Groupe francophone de cytogénétique hématologique (GFCH).
Roche-Lestienne C; Boudry-Labis E; Mozziconacci MJ
Ann Biol Clin (Paris); 2016 Oct; 74(5):511-515. PubMed ID: 27477825
[TBL] [Abstract][Full Text] [Related]
23. Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia.
Steinberg M
Clin Ther; 2007 Nov; 29(11):2289-308. PubMed ID: 18158072
[TBL] [Abstract][Full Text] [Related]
24. Molecular basis for therapeutic decisions in chronic myeloid leukemia patients after allogeneic bone marrow transplantation.
Román J; Alvarez MA; Torres A
Haematologica; 2000 Oct; 85(10):1072-82. PubMed ID: 11025600
[TBL] [Abstract][Full Text] [Related]
25. Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML).
Hanfstein B; Müller MC; Hehlmann R; Erben P; Lauseker M; Fabarius A; Schnittger S; Haferlach C; Göhring G; Proetel U; Kolb HJ; Krause SW; Hofmann WK; Schubert J; Einsele H; Dengler J; Hänel M; Falge C; Kanz L; Neubauer A; Kneba M; Stegelmann F; Pfreundschuh M; Waller CF; Branford S; Hughes TP; Spiekermann K; Baerlocher GM; Pfirrmann M; Hasford J; Saußele S; Hochhaus A; ;
Leukemia; 2012 Sep; 26(9):2096-102. PubMed ID: 22446502
[TBL] [Abstract][Full Text] [Related]
26. Predictive parameters for imatinib failure in patients with chronic myeloid leukemia.
Lekovic D; Gotic M; Milic N; Zivojinovic B; Jovanovic J; Colovic N; Milosevic V; Bogdanovic A
Hematology; 2017 Sep; 22(8):460-466. PubMed ID: 28327053
[TBL] [Abstract][Full Text] [Related]
27. [Tyrosine kinase inhibitors for the treatment of CML].
Heim D
Ther Umsch; 2006 Apr; 63(4):249-54. PubMed ID: 16689455
[TBL] [Abstract][Full Text] [Related]
28. Cytogenetics of chronic myeloid leukaemia.
Chase A; Huntly BJ; Cross NC
Best Pract Res Clin Haematol; 2001 Sep; 14(3):553-71. PubMed ID: 11640869
[TBL] [Abstract][Full Text] [Related]
29. Molecular monitoring of imatinib in chronic myeloid leukemia patients in complete cytogenetic remission: does achievement of a stable major molecular response at any time point identify a privileged group of patients? A multicenter experience in Argentina and Uruguay.
Pavlovsky C; Giere I; Moiraghi B; Pavlovsky MA; Aranguren PN; García J; Fernandez I; Bengió R; Milone J; Labanca V; Uriarte R; Lombardi V; Reinoso FG; Magariños AE; Martinez L; Murro H; Lastiri F; Pavlovsky S
Clin Lymphoma Myeloma Leuk; 2011 Jun; 11(3):280-5. PubMed ID: 21658656
[TBL] [Abstract][Full Text] [Related]
30. Early reduction of BCR-ABL mRNA transcript levels predicts cytogenetic response in chronic phase CML patients treated with imatinib after failure of interferon alpha.
Merx K; Müller MC; Kreil S; Lahaye T; Paschka P; Schoch C; Weisser A; Kuhn C; Berger U; Gschaidmeier H; Hehlmann R; Hochhaus A
Leukemia; 2002 Sep; 16(9):1579-83. PubMed ID: 12200666
[TBL] [Abstract][Full Text] [Related]
31. Dasatinib: from treatment of imatinib-resistant or -intolerant patients with chronic myeloid leukemia to treatment of patients with newly diagnosed chronic phase chronic myeloid leukemia.
Abbott BL
Clin Ther; 2012 Feb; 34(2):272-81. PubMed ID: 22285209
[TBL] [Abstract][Full Text] [Related]
32. [Imatinib therapy in chronic myeloid leukemia].
Egyed M; Kollár B; Rajnics P; Karádi E; Matolcsi A
Orv Hetil; 2008 Aug; 149(32):1509-12. PubMed ID: 18672441
[TBL] [Abstract][Full Text] [Related]
33. Serial monitoring of BCR-ABL transcripts in chronic myelogenous leukemia (CML) treated with imatinib mesylate.
Hardling M; Wei Y; Palmqvist L; Swolin B; Stockelberg D; Gustavsson B; Ekeland-Sjöberg K; Wadenvik H; Ricksten A
Med Oncol; 2004; 21(4):349-58. PubMed ID: 15579919
[TBL] [Abstract][Full Text] [Related]
34. Diagnostic and prognostic cytogenetics of chronic myeloid leukaemia: an update.
Molica M; Massaro F; Breccia M
Expert Rev Mol Diagn; 2017 Nov; 17(11):1001-1008. PubMed ID: 28930482
[TBL] [Abstract][Full Text] [Related]
35. [Molecular-cytogenetic monitoring of different regimens of treatment in patients with chronic myeloid leukemia].
Diachenko LV; Zakharova AV; Aseeva EA; Turkina AG; Khoroshko ND; Vodinskaia LA; Udovichenko AI; Domracheva EV
Ter Arkh; 2004; 76(7):41-4. PubMed ID: 15379126
[TBL] [Abstract][Full Text] [Related]
36. Treatment of Philadelphia chromosome-positive early chronic phase chronic myelogenous leukemia with daily doses of interferon alpha and low-dose cytarabine.
Kantarjian HM; O'Brien S; Smith TL; Rios MB; Cortes J; Beran M; Koller C; Giles FJ; Andreeff M; Kornblau S; Giralt S; Keating MJ; Talpaz M
J Clin Oncol; 1999 Jan; 17(1):284-92. PubMed ID: 10458244
[TBL] [Abstract][Full Text] [Related]
37. Treatment and outcome of 2904 CML patients from the EUTOS population-based registry.
Hoffmann VS; Baccarani M; Hasford J; Castagnetti F; Di Raimondo F; Casado LF; Turkina A; Zackova D; Ossenkoppele G; Zaritskey A; Höglund M; Simonsson B; Indrak K; Sninska Z; Sacha T; Clark R; Bogdanovic A; Hellmann A; Griskevicius L; Schubert-Fritschle G; Sertic D; Guilhot J; Lejniece S; Zupan I; Burgstaller S; Koskenvesa P; Everaus H; Costeas P; Lindoerfer D; Rosti G; Saussele S; Hochhaus A; Hehlmann R
Leukemia; 2017 Mar; 31(3):593-601. PubMed ID: 27568522
[TBL] [Abstract][Full Text] [Related]
38. Practical considerations for monitoring patients with chronic myeloid leukemia.
Branford S; Hughes TP
Semin Hematol; 2010 Oct; 47(4):327-34. PubMed ID: 20875549
[TBL] [Abstract][Full Text] [Related]
39. Chronic phase chronic myeloid leukemia: response of imatinib mesylate and significance of Sokal score, age and disease duration in predicting the hematological and cytogenetic response.
Usman M; Syed NN; Kakepoto GN; Adil SN; Khurshid M
J Assoc Physicians India; 2007 Feb; 55():103-7. PubMed ID: 17571738
[TBL] [Abstract][Full Text] [Related]
40. Ponatinib in the therapy of chronic myeloid leukemia.
Poch Martell M; Sibai H; Deotare U; Lipton JH
Expert Rev Hematol; 2016 Oct; 9(10):923-32. PubMed ID: 27590270
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
